Home / Knowledge Centre /
Case study

$5M Saved for Top 20 Global Pharma Company with Almac Supply Chain Oversight

One of the top 20 global pharmaceutical companies conducted a phase III clinical trial to compare the efficacy, safety, and tolerability of multiple doses of Investigational Medicinal Products (IMPs) with a comparator drug product for the treatment of Diabetes.

At mid-trial, they engaged Almac’s Supply Chain Management (SCM) experts to devise a new optimal drug supply strategy to prevent further stock-outs. The study was a randomised, double-blinded, parallel group trial. This was a truly global phase III trial with 44 countries participating across Europe, United States, Latin America, Asia and Africa.

Almac faced a number of significant challenges to maintain and optimise the IMP supply chain. The SCM assigned conducted a full review of historical patient event data from the Interactive Response Technology (IRT) report, and identified trend in dose titrations from patients enrolled in the study.
Almac saved the client $4.95 million per year while preventing further stock-outs.

View Resource
Almac Logo

Almac Clinical Services

Guided by our extensive clinical supply experience and expertise, Almac Clinical Services  is  recognised as an innovative,  global solution provider within the specialised and complex market of clinical trial supply.

Our integrated and adaptable solutions offer the most flexible approach to support the delivery of global clinical trials from protocol right through to patient delivery.

Our core purpose is to be the partner of choice, to deliver the next generation of health care solutions effectively and to focus on winning for you and your patients.

Learn More

Download here instantly

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies